HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NBTY Advances Into Personal-Care Space With Organic Doctor Acquisition

This article was originally published in The Rose Sheet

Executive Summary

Dietary supplement manufacturer NBTY purchases the U.K.-based Dr. Organic/Organic Doctor personal-care line, continuing the firm's focus on building its branded consumer business. The deal helps diversify NBTY's health and wellness portfolio and accelerate its entry in the mass-market beauty and skin-care segments.

You may also be interested in...



KKR Steers Nature's Bounty With Carlyle In Back Seat After Seven-Year Ride

Since acquiring Nature's Bounty in 2010 and taking the publicly traded firm private, Carlyle could have been at the helm longer than executives at the private equity firm intended or expected, exceeding the five-year plan typical for similar investments.

Carlyle Trims Nature's Bounty Assets: Private Equity Rolls In Supplement Space

Carlyle's $2.2bn sale of Nature's Bounty's Holland & Barrett business to a Russian investment fund is the latest sign of the private equity sector's continuing interest in the health and wellness space.

NAD Sends Vogue Back To Drawing Board For OGX Packaging, Claims

Advertising watchdog agrees with challenger Unilever that product names for Vogue International's OGX (previously Organix) line, such as Renewing Argan Oil of Morocco Shampoo, connect exotic ingredients to touted benefits without adequate supporting evidence. NAD also weighs in on implied sulfate-free claims for one OGX product, marketed as "Zero SLS/SLES."

UsernamePublicRestriction

Register

RS019629

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel